The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities. (PubMed, Clin Lymphoma Myeloma Leuk) - Sep 11, 2026 - "A major focus was immunotherapy integration into frontline therapy, particularly blinatumomab as an emerging standard of care and inotuzumab ozogamicin as an investigational agent, and their potential to enable chemotherapy de-escalation. The integration of immunotherapy into frontline ALL therapy represents a paradigm shift with potential to improve outcomes while reducing treatment burden. However, careful attention to CNS disease control, emerging toxicities, and preservation of the remarkable achievements in childhood ALL therapy remains essential as the field advances."
Journal • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Oncology
|
|
Atsushi Manabe; Carmelo Rizzari; Ching-Hon Pui; David T Teachey; Hiroto Inaba; Jiaoyang Cai; Lewis B Silverman; Martin Schrappe; Mats M Heyman; Mignon L Loh; Rob Pieters; Sarah Elitzur; Seth E Karol; Stephen P Hunger
|